Disclosure of Unlabeled Use and Investigational Product
This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will review challenges with standard-of-care treatments for neovascular age-related macular degeneration (nAMD), particularly the need for frequent injections, and the use of variable dosing strategies to address these challenges. The session will also review the safety and efficacy of newer strategies to improve treatment duration and patient adherence, including longer-acting drugs, longer-acting technologies, and gene therapies.
This activity is designed for an audience of ophthalmologists, optometrists, and other members of the healthcare team who treat patients with nAMD.
Upon completion of the educational activity, participants should be able to:
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at
ketrea@akhcme.com
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.00
AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AKH Inc., Advancing Knowledge in Healthcare designates this asynchronous activity for a maximum of 1.0 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported from an independent medical education grant from Alcon, Genentech, Regenxbio, Tarsus, Théa, and Visus.
Name
Relationship
Commercial Interest
Session Faculty
Mohammad Rafieetary, OD (faculty)
Consultant
Heidelberg
Consultant, Speaker
Apellis
Consultant, Speaker
Iveric Bio
Consultant
OcuTerra
Speaker
Optos
Priya Vakharia, MD (faculty)
Consultant, Research, Speaker
Regeneron
Consultant
Alimera
Consultant
Bausch + Lomb
Consultant
Notal Vision
Consultant, Research
EyePoint
Consultant, Research, Speaker
Iveric Bio
Consultant, Speaker
Apellis
Consultant
Novartis
Consultant
Ocuphire
Stock
Network Eye
Stock
Quad C/PRISM
Research
4DMT
Research
Bayer
Research
Opthea
Research
Ocular Therapeutix
Research
Mylan
Research
Gemini
Research
Kodiak
Research
NGM
Research
Recens Medical
Research
Alkahest
Research
Ionis
Research
RegenxBio
Research
Unity
Research
Alexion
Research. Speaker
Genentech
Yoshihiro Yonekawa, MD (moderator)
Consultant
Alcon
Consultant
Pykus
Consultant
Versant Health
Dorothy Caputo, MA, BSN, RN, VP, Healthcare Continuing Education & Operations
N/A
Nothing to disclose
Michele Bielarski, RN (planner/reviewer)
N/A
Nothing to disclose
AKH Inc. Staff and Planners
N/A
Nothing to disclose
International Healthcare Media dba
International Healthcare Education Staff and
Planners
N/A
Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.
Overcoming Adherence Challenges in Neovascular AMD: Exploring Variable Dosing Strategies and New Treatment Pathways and Delivery Systems
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.